ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
Overall ABOS gets a fundamental rating of 2 out of 10. We evaluated ABOS against 587 industry peers in the Biotechnology industry. The financial health of ABOS is average, but there are quite some concerns on its profitability. ABOS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ABOS had negative earnings in the past year.
In the past year ABOS has reported a negative cash flow from operations.
ABOS had negative earnings in each of the past 5 years.
ABOS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ABOS has a better Return On Assets (-16.89%) than 85.13% of its industry peers.
With an excellent Return On Equity value of -19.62%, ABOS belongs to the best of the industry, outperforming 87.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.89% | ||
| ROE | -19.62% | ||
| ROIC | N/A |
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ABOS has more shares outstanding
ABOS has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.22 indicates that ABOS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ABOS's Altman-Z score of 2.22 is fine compared to the rest of the industry. ABOS outperforms 71.28% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that ABOS is not too dependend on debt financing.
The Debt to Equity ratio of ABOS (0.11) is worse than 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.22 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ABOS has a Current Ratio of 19.01. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 19.01, ABOS belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
ABOS has a Quick Ratio of 19.01. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 19.01, ABOS belongs to the best of the industry, outperforming 94.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.01 | ||
| Quick Ratio | 19.01 |
3. Growth
3.1 Past
The earnings per share for ABOS have decreased by -1.89% in the last year.
EPS 1Y (TTM)-1.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -1.84% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.74%
EPS Next 2Y-14.99%
EPS Next 3Y-19.64%
EPS Next 5Y-1.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ABOS. In the last year negative earnings were reported.
Also next year ABOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABOS's earnings are expected to decrease with -19.64% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.99%
EPS Next 3Y-19.64%
5. Dividend
5.1 Amount
No dividends for ABOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACUMEN PHARMACEUTICALS INC
NASDAQ:ABOS (5/7/2024, 7:00:00 PM)
After market: 3.52 +0.16 (+4.76%)3.36
-0.2 (-5.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap201.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.89% | ||
| ROE | -19.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 19.01 | ||
| Quick Ratio | 19.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-10.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y